Private-equity firm BC Partners has struck a deal to acquire a majority stake in Synthon International Holding.

Calls are mounting for the EU to make the centralized procedure mandatory for follow-on versions of non‐biological complex drugs and for better regulatory alignment with the US and other countries.

Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.

Like in the US, Teva's more convenient three-times-a-week dosage form of Copaxone is now facing competition in Europe from a generic, in this case one developed by the Netherlands' Synthon and Iceland's Alvogen.